Cyclo Therapeutics, Inc. (CYTH)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Cyclo Therapeutics, Inc. (CYTH)
Go deeper and ask any question about CYTH
Company Performance
Current Price
as of Oct 03, 2024$0.71
P/E Ratio
N/A
Market Cap
$20.39M
Description
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
Metrics
Overview
- HQGainesville, FL
- SectorHealth Technology
- IndustryBiotechnology
- TickerCYTH
- Price$0.7107-2.78%
Trading Information
- Market Cap$20.39M
- Float57.84%
- Average Daily Volume (1m)45,868
- Average Daily Volume (3m)77,652
- EPS-$0.88
Company
- Revenue$1.13M
- Rev Growth (1yr)5.11%
- Net Income-$5.98M
- Gross Margin-656.37%
- EBITDA Margin-4,576.22%
- EBITDA-$5.63M
- EV$38.25M
- EV/Revenue33.77
- P/EN/A
- P/S17.97
Documents
SEC Filings
Factset Street Account
Factset